NAGEMEDIUM SIGNALMANAGEMENT10-K

ChromaDex Corporation completed a comprehensive corporate rebranding to Niagen Bioscience, Inc. with new ticker symbol NAGE, while delivering solid financial growth across key metrics.

The name change from ChromaDex to Niagen Bioscience represents a strategic repositioning around the company's flagship NAD+ precursor ingredient, potentially signaling a more focused business strategy. The rebrand coincides with strong operational performance, suggesting management confidence in the company's market position and growth trajectory.

Comparing 2026-03-04 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

The company demonstrated robust financial expansion with revenue growing 30% to $129.4M and gross profit increasing 35% to $83.2M, indicating improving operational efficiency. The balance sheet strengthened considerably with cash growing 64% to $44.5M and stockholders' equity expanding 66% to $76.5M, while total debt doubled to $5.0M from a low base. Inventory declined 37% to $9.2M, suggesting improved working capital management and demand fulfillment efficiency.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
+100%
$2.5M→$5.0M

Debt increased 100% — substantial leverage increase; assess whether deployed for growth or covering losses.

Stockholders Equity
Balance Sheet
+66%
$46.1M→$76.5M

Equity base grew 66% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+63.6%
$27.2M→$44.5M

Cash position surged 63.6% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+55.8%
$68.3M→$106.4M

Asset base grew 55.8% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+51%
$64.1M→$96.8M

Current assets grew 51% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-43.8%
$1.3M→$743K

Capex reduced 43.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
-36.7%
$14.5M→$9.2M

Inventory drawn down 36.7% — strong sell-through or deliberate destocking; watch for supply constraints.

Gross Profit
P&L
+35.1%
$61.6M→$83.2M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Liabilities
Balance Sheet
+34.7%
$22.2M→$29.9M

Liabilities grew 34.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Revenue
P&L
+29.9%
$99.6M→$129.4M

Revenue growing 29.9% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-03-04
ADDED
(Exact name of Registrant as specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation) (I.R.S.
We caution you therefore, against relying on any of these forward-looking statements.
Business Unless otherwise indicated or the context otherwise requires, references to the Company, Niagen Bioscience, we, us and our refer to Niagen Bioscience, Inc.
On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).
Prior to its dissolution, Healthspan Research, LLC contributed its assets and liabilities to ChromaDex, Inc., a wholly owned subsidiary of ChromaDex Corporation, Effective March 19, 2025, the Company changed its name to Niagen Bioscience, Inc.
In connection with the Company s new name, the Company changed the ticker symbol for the Company s common stock on Nasdaq, to NAGE .
Company Overview We are a global bioscience company dedicated to promoting healthy aging.
Our team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism and is present in every cell of the human body.
NAD+ levels naturally decline with age, by up to 65% between ages 30 and 70, and can also be impacted by poor diet, excess alcohol consumption, and certain disease states.
Increasing NAD+ levels through NAD+ precursors, calorie restriction, or moderate exercise has been shown to support healthy cellular function.
REMOVED
Commission file number 001-37752 CHROMADEX CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation) (I.R.S.
We caution you therefore against relying on any of these forward-looking statements.
Business Unless otherwise indicated or the context otherwise requires, references to the Company, ChromaDex, we, us and our refer to ChromaDex Corporation and its consolidated subsidiaries.
ChromaDex Corporation was traded on the over-the-counter market under the symbol CDXC.
On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market under the symbol CDXC.
ChromaDex, Inc., a wholly owned subsidiary of ChromaDex Corporation, was originally formed as a California corporation on February 19, 2000.
Prior to its dissolution, Healthspan Research, LLC contributed its assets and liabilities to ChromaDex, Inc.
Company Overview ChromaDex is a global bioscience company dedicated to healthy aging.
Our team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body.
In addition to age, other factors linked to NAD+ depletion include poor diet, excess alcohol consumption and a number of disease states.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →